(Press-News.org) Australian researchers have identified a potentially treatable subtype of pancreatic cancer, which accounts for about 2% of new cases. This subtype expresses high levels of the HER2 gene. HER2-amplified breast and gastric cancers are currently treated with Herceptin.
Pancreatic cancer is the fourth leading cause of cause of cancer death in Western societies, with a 5-year survival rate of less than 5%. It is a molecularly diverse disease, meaning that each tumour will respond only to specific treatments that target its unique molecular make-up.
A new study, published in Genome Medicine, used a combination of modern genetics and traditional pathology to estimate the prevalence of HER2-amplified pancreatic cancer. Pancreatic surgeon Professor Andrew Biankin, from Sydney's Garvan Institute of Medical Research and the Wolfson Wohl Cancer Research Centre at the University of Glasgow, worked with pathologist Dr Angela Chou and bioinformatician Dr Mark Cowley from Garvan, as well as cancer genomics specialist Dr Nicola Waddell from the Queensland Centre for Medical Genomics at the University of Queensland.
Using data sourced from the Australian Pancreatic Cancer Genome Initiative1 (APGI), the team identified a patient with high-level HER2 amplification. Using whole genome DNA sequencing of the tumour, Dr Nicola Waddell pinpointed the specific region of the genome that contains HER2.
Dr Angela Chou then performed detailed histopathological characterisation of HER2 protein in tissue samples taken in the past from 469 pancreatic cancer patients. This produced a set of standardised laboratory testing guidelines for testing HER2 in pancreatic cancer, and showed the frequency of HER2 amplified pancreatic cancer of 2.1%.
Dr Chou also found that - like HER2-amplified breast cancer patients - the cancers of those with HER2-amplification in the pancreas tended to spread to the brain and lung, rather than the norm, which is the liver.
Dr Mark Cowley analysed all the data generated by the project and compared it to other sequences from many cancer types produced by the International Cancer Genome Consortium and The Cancer Genome Atlas project. "HER2 amplification was prevalent at just over 2% frequency in 11 different cancers," he observed.
"We make the case that if HER2 is such a strong molecular feature of several cancers, then perhaps recruiting patients to clinical trials on the basis of the molecular features rather than the anatomical region of their cancer could have a significant impact on patient outcomes, and still make economic sense for pharmaceutical companies. Such "Basket" trials, as they are sometimes called, may advance treatment options for those with less common cancer types."
In Australia, 2,000 people are diagnosed with pancreatic cancer each year, and so 40 are likely to have the HER2 amplified form.
While Herceptin is available through the Pharmaceutical Benefits Scheme for treating breast and gastric cancer, it is not available for treating HER2-amplified pancreatic cancer as no clinical trial has yet been conducted to determine the drug's efficacy in that case.
The Garvan Institute in collaboration with the Australasian Gastro-Intestinal Trials Group, is recruiting pancreatic cancer patients through the APGI for a pilot clinical trial, known as 'IMPaCT'2, to test personalised medicine strategies.
Potential patients will be screened for specific genetic characteristics, including high levels of HER2, based on their biological material sequenced as part of the APGI study. Once these characteristics are confirmed,
patients will be randomised to receive standard therapy or a personalised therapy based on their unique genetic make-up.
###
NOTES
1. The Australian Pancreatic Cancer Genome Initiative (APGI) is the Australian arm of the International Cancer Genome Consortium (ICGC), and aims to catalogue all the genetic changes in pancreatic cancer by analysing the biological material from patients diagnosed with Pancreatic cancer.
It is made up of a range of specialists - surgeons, pathologists, nurses - and researchers in pancreatic cancer across the country. The initiative also includes significant contributions from 15 academic and clinical centres across the country and internationally.
2. The IMPaCT trial (Individualised Molecular Pancreatic Cancer Therapy trial) is a randomised, open label, phase II trial assessing standard first line treatment with Gemcitabine or personalised treatment based on tumour molecular signature in patients with recurrent or metastatic pancreatic cancer to evaluate feasibility and impact on progression free survival. This study is a collaboration between the Australasian Gastro-Intestinal Trials Group and the Australian Pancreatic Cancer Genome Initiative at the Garvan Institute of Medical Research, Sydney Catalyst and the NHMRC Clinical Trials Centre, University of Sydney.
Twenty patients will be enrolled in a pilot stage to determine the technical feasibility of randomising patients to a personalised treatment approach (including the logistics of recruitment, delivery of personalised treatment and general trial conduct).
Potential treatment for a specific kind of pancreatic cancer
2013-09-16
ELSE PRESS RELEASES FROM THIS DATE:
Study recommends strategies for improved management of fresh market spinach
2013-09-16
SALINAS, CA -- Throughout California's fertile central coast region, fresh spinach is a high-production, high-value crop. Spinach can be finicky, requiring sufficient nitrogen fertilizer and irrigation to ensure ideal growth, and to meet industry quality standards such as its defining deep green color. These production practices -- combined with a shallow root system and the crop's intensive production cycle -- can increase the potential of detrimental nitrate leaching. Recent water quality monitoring in the region has found widespread incidences of NO3 levels that exceed ...
Chemistry magic promises better medicine with fewer side-effects
2013-09-16
A gentler new chemistry promises cleaner and subsequently far safer pharmaceuticals. The ground-breaking method, developed by a chemistry research group at the University of Copenhagen, is now published in the internationally renowned journal, Chemical Communications, as "Site-selective three component reaction for dual functionalization of peptides".
Knud J. Jensen, the group's leader, is convinced that the method will become pivotal in the development of new pharmaceuticals. "This method opens a new chest of tools. I believe, it will be applied to pharmaceutical research ...
Could oxytocin be useful in treating psychiatric disorders?
2013-09-16
Philadelphia, Pa. (September 16, 2013) – The hormone oxytocin could play a role in treating psychiatric disorders such as autism and schizophrenia, according to a review article in the September Harvard Review of Psychiatry. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Among other biological effects, oxytocin is "an important regulator of human social behaviors," according to the research review by Dr David Cochran of University of Massachusetts Medical School and colleagues. They discuss the preliminary but encouraging ...
Graphene photodetector integrated into computer chip
2013-09-16
This news release is available in German. Today, most information is transmitted by light – for example in optical fibres. Computer chips, however, work electronically. Somewhere between the optical data highway and the electronic chips, photons have to be converted into electrons using light-detectors. Scientists at the Vienna University of Technology have now managed to combine a graphene photodetector with a standard silicon chip. It can transform light of all important frequencies used in telecommunications into electrical signals. The scientific results have ...
As opioid use soars, no evidence of improved treatment of pain
2013-09-16
A new study led by the Johns Hopkins Bloomberg School of Public Health finds that during a decade when prescription opioid use has skyrocketed, the identification and treatment of pain has failed to improve, and the use of non-opioid analgesics has plateaued, or even declined. The study was published online September 13 in the journal Medical Care.
"There is an epidemic of prescription opioid addiction and abuse in the United States," notes G. Caleb Alexander, MD, MS, associate professor of Epidemology and Medicine and co-director of the Johns Hopkins Center for Drug ...
Specific sugar molecule causes growth of cancer cells
2013-09-16
In co-operation with a research group from Singapore, scientists at University of Copenhagen have shown that immature sugar molecules in the form of truncated O-glycans aid growth properties of cancer cells. Previously, scientists have not been able to decode the significance of these truncated O-glycans, and therefore, the results, which were recently published in the journal PNAS, represent an important contribution to understanding the growth of cancer cells as well as the work towards developing a cure that can limit or stop the growth.
Catharina Steentoft, PhD student ...
Schizophrenia: It's in the wiring of the brain
2013-09-16
Philadelphia, PA, September 16, 2013 – Just as wires must be insulated to effectively carry electrical impulses, nerve cells must be insulated by myelin to effectively transmit neural impulses. Using typical magnetic resonance imaging or MRI, one can visually distinguish parts of the brain that look white and parts that look gray. Myelin is most prevalent in the white matter because this component of the brain tissue is principally comprised by the nerve cell projections (axons) that are covered by myelin and that transmit information from one part of the brain to another. ...
Intelligent use of electronic data helps the medicine go down, say researchers
2013-09-16
Electronic data routinely gathered in hospitals can be used as a warning system for missed doses of prescribed medicine and making improvements to patient safety, says a new study.
A team from the Universities of Leicester and Birmingham found that the secondary use of data from an electronic prescribing and decision support system in an English hospital led to a 'substantial and sustained' reduction in rates of missed or delayed doses of medicines.
Published in the world-leading health policy journal Milbank Quarterly, the study looked at how using the electronic ...
Hospital study finds connection between dementia, delirium and declining health
2013-09-16
More than half of all patients with pre-existing dementia will experience delirium while hospitalized. Failing to detect and treat their delirium early leads to a faster decline of both their physical and mental health, according to health researchers.
"This study is important, as delirium is often overlooked and minimized in the hospital setting, especially in persons with dementia," said Donna M. Fick, Distinguished Professor of Nursing at Penn State and principal investigator for this study. "And it illustrates that delirium is deadly, costly and impacts patient functioning." ...
Environmentally friendly cement is stronger than ordinary cement
2013-09-16
New research from the Niels Bohr Institute shows that cement made with waste ash from sugar production is stronger than ordinary cement. The research shows that the ash helps to bind water in the cement so that it is stronger, can withstand higher pressure and crumbles less. At the same time, energy is saved and pollution from cement production is reduced. The results are published in the scientific journal, Scientific Reports.
Cement is comprised of chalk and clay, which are mixed together and heated at high temperatures in a cement kiln. The mixture is then crushed ...